On Friday, Royal Bank of Canada (NYSE:RY)’s shares declined -1.10% to $63.63.
Royal Bank of Canada (RY) declared its quarterly common share dividend of 77 cents per share, payable on and after August 24, 2015 , to common shareholders of record at the close of business on July 27, 2015 .
The board also declared dividends on the following Non-Cumulative First Preferred Shares, payable on and after August 24, 2015 , to shareholders of record at the close of business on July 27, 2015 .
Royal Bank of Canada, together with its auxiliaries, operates as a diversified financial service company worldwide. The company operates through five segments: Personal & Commercial Banking, Wealth Administration, Insurance, Investor & Treasury Services, and Capital Markets.
Axiall Corp (NYSE:AXLL)’s shares gained 0.05% to $37.71.
The Board of Directors of Axiall Corp (AXLL) declared a regular quarterly dividend of 16 cents per share of common stock. The dividend is payable July 10, 2015, to shareholders of record at the close of business on June 26, 2015.
Axiall Corporation manufactures and markets chemicals and building products in the United States and internationally. The company operates through three segments: Chlorovinyls, Building Products, and Aromatics.
At the end of Friday’s trade, Dunkin Brands Group Inc (NASDAQ:DNKN)‘s shares up 0.95% to $53.36.
Friday, June 5th is National Donut Day and Dunkin Brands Group Inc (DNKN) will commemorate the holiday by offering guests a free donut* of their choice (while supplies last) with the purchase of any beverage. The offer is good all day on June 5th at participating Dunkin’ Donuts restaurants nationwide. Additionally, Dunkin’ Donuts is assisting guests all around the world celebrate the joy of donuts, making this special offer accessible in its restaurants across the globe.
Dunkin Brands Group, Inc., together with its subsidiaries, develops, franchises, and licenses quick service restaurants under the Dunkin Donuts and Baskin-Robbins brands worldwide.
The Medicines Company (NASDAQ:MDCO), ended its Friday’s trading session with -0.78% gain, and closed at $28.36.
The Medicines Company (MDCO) presented the results of a Phase 1 study for MDCO-216 that showed that the drug had a noteworthy remodeling effect on HDL particles, which correlated with raised ABCA1-mediated cholesterol efflux. This mechanism of HDL remodeling and raised cholesterol efflux may drive the removal of deposited cholesterol from vessel walls to reduce plaque burden in patients with atherosclerotic disease. The findings were presented at the 17th International Symposium on Atherosclerosis, May 23-26, in Amsterdam, The Netherlands.
MDCO-216 is a complex of dimeric recombinant apolipoprotein A-1 Milano (ApoA-1 Milano) and a phospholipid (POPC) which was developed in an attempt to mimic pre-beta HDL and induce cholesterol efflux, the first step in reverse cholesterol transport, causing removal of cholesterol from the artery walls.
The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, in addition to acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
